Neumora Therapeutics
demonstrated statistically significant and clinically meaningful improvements in depression and anhedonia despite inclusion of mild patients | Neumora Therapeutics
Company
Deck Type
IPO
Sector
Industry
Deck date
September 2023
Slide
32 of 32
Related slides by other companies
Theravance Biopharma
Investor Conference
November 2022
improvements in plasma were seen in patients with | Theravance Biopharma
P3 Health Partners
Investor Conference
November 2022
significant improvements | P3 Health Partners
Oculis
Investor Presentation
July 2023
of patients with line improvement in at week | Oculis
DICE Therapeutics
Results
October 2022
demonstrated a favorable safety and tolerability profile in occurring in patients in phase dice | DICE Therapeutics
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io